Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRLX 93936 in Relapsed/Refractory Multiple Myeloma
NCT01695590Phase 2Unknown
- Sponsor
- Prolexys Pharmaceuticals
- Start
- Mar 2012
- Primary completion
- Mar 2014
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of PRLX 93936 in multiple myeloma (MM), sponsored by Prolexys Pharmaceuticals. Status: unknown.
02
Drugs
PRLX 93936
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01695590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695590.